Credit Cards by Nick Youngson is licensed under CC BY-SA 3.0

On February 20, 2025, ATR led a coalition letter addressed to members of Congress raising concerns with a finalized rule from the Consumer Financial Protection Bureau that would eliminate medical debt from consideration in credit reports.  

The full letter can be read here. 

The letter highlights how Regulation V of the Fair Credit Reporting Act permits credit agencies to collect medical debt information for credit evaluation purposes. The consequences of arbitrarily amending Regulation V would have consumers for both credit agencies and consumers alike, distorting and diluting the creditworthiness of borrowers. 

Whitewashing credit data distorts the allocation of credit to individuals and businesses across the U.S. The FCRA was crafted to allow consideration of medical debt in credit reports. Eliminating medical debt will have a domino effect where additional consumer data points could be incrementally removed from credit reports. Removing this information from consideration will reduce the accuracy of credit assessments and distort the true credit worthiness of borrowers. This will in turn lead to deserving borrowers losing access to credit and reducing economic activity. 

The CFPB attempted to justify its actions by reasoning the rule would rectify issues related to penalties arising from billing errors or inaccuracies in how consumers are charged. However, such minute errors do not warrant promulgating blanket rules with large-scale economic consequences. The rule would result in credit reports failing to capture all debts a borrower owes to creditors, generating a dangerous precedent that breeds moral hazard.  

Misrepresenting the true creditworthiness of a borrower will result in consumers over-leveraging themselves with debt levels beyond what they can reasonably afford. This rule would generate moral hazard akin to the subprime mortgage crisis, where reckless lending created severe financial instability and triggered mass defaults. 

Further complicating the legitimacy of the rule, the coalition expressed concern that the CFPB exceeded its statutory authority under its interpretation of the FCRA and CFPA. Congress has passed no legislation demanding the issue of medical debt be re-examined or altered in credit reporting standards. The Administrative Procedure Act confines agency rulemaking solely to aligning with congressional intent to prevent executive overreach. As such, the expansive and liberal interpretation of the FCRA and CFPB used to justify the rule may violate the APA.  

It also remains uncertain whether the CFPB’s interpretation of its authority under the FCRA and CFPA can be justified. The Administrative Procedure Act requires agencies to administer rulemaking proposals in line with the intent of Congressional legislation. To date, no legislation has targeted the elimination of medical debt from credit assessments, raising doubts over whether the CFPB possesses the statutory authority to issue such a rule. 

In evaluating the total economic impact of the regulation, small healthcare practices could be adversely affected, creating unwanted consequences that would reverberate throughout the healthcare market such as higher premiums.  

Removing consideration of medical debt also will have detrimental effects on the U.S. healthcare industry. Small healthcare practices could see a sharp reduction in cash flow, which could lead to rising healthcare costs. The knock-on effects could impact insurance companies and lead to a rise in healthcare premiums. 

The letter recognizes the rule diverges from foundational free-market principles that allow creditors to thoroughly assess the creditworthiness of potential borrowers to mitigate unwanted risk. Consequently, the signatories to the letter call on Congress to nullify the rule through a joint resolution of disapproval under the Congressional Review Act.  

It is clear the CFPB is attempting to extend its rulemaking powers beyond the limits of its own statutory authority. Lawmakers should continue to safeguard the existence of a well-functioning, transparent credit market by rejecting proposals that threaten to derail the integrity of credit assessments and increase lending risks. For these reasons, we urge you to nullify this rule through a joint resolution of disapproval under the Congressional Review Act. 

Read the full letter here.